WNTresearch
WNTresearchWNTresearchWNTresearch

WNT research

  • WntResearch
    • About WntResearch
      • Vision
      • History
      • business Model
      • market Potential
    • Management
    • Board
    • Scientific advisors
    • NOMINATION COMMITTÈE
  • Tumour Biology
    • metastases
    • WNT signaling
    • WNT5A
  • Foxy-5
    • About Foxy-5
    • Clinical trials
      • Phase 1 study
      • Phase 2 study
    • timetable
    • Partners
      • SMS Oncology
      • Biovica
      • SAGA diagnostics
  • Box-5
    • About Box-5
  • Patents
  • Investor
    • Financial reports
    • Share issues
    • Annual General meeting
    • The Share
    • Articles of association
  • NEWS
    • Press Releases
    • News
    • presentations
  • Contact
  • English
    • Swedish

Author Archives: David

WNTresearch   →  Articles by: David
01
Oct
Date October 1, 2020
Categories Uncategorized

Anders Rabbe is appointed acting CEO

Link

Author David
24
Sep
Date September 24, 2020
Categories Uncategorized

BioStock publishes interview with CEO Peter Morsing

Link

Author David
09
Jul
Date July 9, 2020
Categories Uncategorized

BioStock publishes summer interview with CEO Peter Morsing

Link

Author David
17
Apr
Date April 17, 2020
Categories Uncategorized

Wntresearch publishes quarterly report Q1 2020

Link

Author David
15
Apr
Date April 15, 2020
Categories Uncategorized

CEO interview about status in ongoing phase 2-study

Link

Author David
01
Oct
Date October 1, 2019
Categories Uncategorized

Biostock interviews the CEO

Author David
08
Aug
Date August 8, 2019
Categories Uncategorized

WntResearch increases resources for out-licensing Foxy-5

Link

Author David
30
Apr
Date April 30, 2019
Categories Uncategorized

Year-end report 2018

Länk

Author David
15
Apr
Date April 15, 2019
Categories Uncategorized

Intervju med Ramon Salazar, Coordinating Principal Investigator för fas 2-studien

Link

Author David
09
Apr
Date April 9, 2019
Categories Uncategorized

Intervju med professor Ingvar Syk

Link

Author David
1 2 Next page

Search

Categories

  • Emission 2
  • Uncategorized 11
  • VD Brev 1

Recent Posts

  • BioStock publishes interview with acting CEO!October 27, 2020
  • Anders Rabbe is appointed acting CEOOctober 1, 2020
  • BioStock publishes interview with CEO Peter MorsingSeptember 24, 2020
  • BioStock publishes summer interview with CEO Peter MorsingJuly 9, 2020
  • Wntresearch publishes quarterly report Q1 2020April 17, 2020

Archives

  • October 2020
  • September 2020
  • July 2020
  • April 2020
  • October 2019
  • August 2019
  • April 2019
  • March 2019
A new approach to fight tumour spread!
Foxy-5 is a unique drug candidate:
Significant medical need, first-in-class, unique mode of action, excellent pharmacokinetics, strong preclinical efficacy data, favourable safety profile

QUICK LINKS

  • Phase 2 study
  • Press Releases
  • shares

LATEST NEWS

  • BioStock publishes interview with acting CEO! October 27, 2020
  • Anders Rabbe is appointed acting CEO October 1, 2020
Copyright © All rights reserved, design by Design & Animation in Vellinge AB
Prenumeration på Cision News

Din prenumeration sparades!





Du kommer att prenumerera på följande:

Sökning: 

Du kommer att prenumerera på alla nyheter från WntResearch som hör till Sverige.

Cision kommer att lagra ovanstående uppgifter för att löpande kunna skicka dig den information du har valt att prenumerera på. Dina personuppgifter delas inte externt och kommer inte att användas i något annat syfte än att förse er med efterfrågad information. I samtliga utskick du får från oss medföljer länk till sida där du kan ändra eller avsluta din prenumeration. Läs mer om hur Cision behandlar personlig information här.

Genom att klicka på “Prenumerera” kommer du få ett mail med en länk som du måste följa för att aktivera din prenumeration. Om du inte har aktiverat din prenumeration inom 25 dagar så kommer ovanstående uppgifter att tas bort från våra system.